ストックスクリーナーアプリを入手
0.6582
1.47%
-0.0098
アフターアワーズ：
.64
-0.0182
-2.77%
前日終値:
$0.668
開ける：
$0.651
24時間の取引高:
44,455
Relative Volume:
0.08
時価総額：
$5.20M
収益：
-
当期純損益:
$-6.07M
株価収益率:
-0.1139
EPS:
-5.78
ネットキャッシュフロー:
$-7.34M
1週間 パフォーマンス:
-4.33%
1か月 パフォーマンス:
-4.54%
6か月 パフォーマンス:
-42.77%
1年 パフォーマンス:
-49.76%
1日の値動き範囲:
$0.651
$0.67
1週間の範囲:
$0.646
$0.7392
52週間の値動き範囲:
$0.5704
$3.00
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
名前
Adial Pharmaceuticals Inc
セクター
電話
434-422-9800
住所
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
ADIL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.6582 | 5.44M | 0 | -6.07M | -7.34M | -5.78 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2018-10-30 | 開始されました | Maxim Group | Buy |
| 2018-10-11 | 開始されました | Dawson James | Buy |
Adial Pharmaceuticals Inc (ADIL) 最新ニュース
Adial Pharmaceuticals (ADIL) Files to Sell Over 6 Million Shares - GuruFocus
Adial Pharmaceuticals Faces Nasdaq Non-Compliance Notice - TipRanks
Adial Pharmaceuticals (ADIL) Files to Sell Over 6 Million Shares | ADIL Stock News - GuruFocus
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
ADIL Q2 EPS Increased by Brookline Capital Management - Defense World
Adial Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharmaceuticals sets new proposal deadline By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals sets new proposal deadline - Investing.com
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stoc - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Q1 2025 Financial Results and Business Update - TradingView
Adial Pharmaceuticals Advances AUD Drug to Phase 3, Cuts Losses by 66% in Q1 2025 Earnings - Stock Titan
ADIAL PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asth - GuruFocus
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asthma Drug Development | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - The Manila Times
Adial Pharmaceuticals (ADIL) Projected to Post Quarterly Earnings on Tuesday - Defense World
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment - Investing.com Nigeria
FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04 - Psychiatric Times
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA - marketscreener.com
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program - AOL.com
Adial Pharmaceuticals (ADIL) Receives FDA Green Light for Phase 3 Meeting | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration - The Manila Times
Renaissance Technologies LLC Purchases New Stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Richmond InnoAdial Pharmaceuticals raises $2.75M - The Business Journals
Biotech Alert: Searches spiking for these stocks today - TipRanks
ADIL: Adial Pharmaceuticals Boosts Patent Portfolio with New Approval | ADIL Stock News - GuruFocus
Geode Capital Management LLC Grows Stock Holdings in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Adial Pharmaceuticals secures $2.75 million through warrant exercise By Investing.com - Investing.com Nigeria
Press Release Distribution & PR Platform - ACCESS Newswire
Adial Pharmaceuticals secures $2.75 million through warrant exercise - Investing.com
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds - GlobeNewswire
Healthcare Investor Commits $2.75M to Adial Pharmaceuticals Addiction Treatment Pipeline - Stock Titan
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring - Asianet Newsable
Adial Pharmaceuticals Inc: Rising -76.71% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
How will Adial Pharmaceuticals Inc’s (ADIL) earnings compare to estimates this quarter? - uspostnews.com
Adial Pharmaceuticals (ADIL) Secures Patent for Novel Addiction Treatment Method | ADIL Stock News - GuruFocus
Adial Pharmaceuticals secures patent for addiction treatment - Investing.com Australia
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders - GlobeNewswire
Revolutionary Patent Links Genetic Markers to Personalized Addiction Treatment Success - Stock Titan
EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders - Yahoo
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals Inc (ADIL) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
1.24%
大文字化:
|
ボリューム (24 時間):